The Role of AI in Empowering Early Lung Cancer Detection & Transforming Patient Outcomes
AI-powered solutions for opportunistic lung cancer detection using routine chest X-rays offer hope for improved early diagnosis and survival rates.
Paradigm Launches with $203M to Transform Clinical Trial Recruitment
Paradigm, a new startup co-incubated by ARCH Venture Partners and General Catalyst, recently launched with $203 million in Series A funding. The company is focused on improving equitable access to trials by creating a less fragmented and more efficient clinical research ecosystem.
presented by
5 Major Trends Emerging in Healthcare Benefits in 2025
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
Persephone rakes in $15M to support country’s biggest cancer microbiome study
Persephone Biosciences, a preclinical biotech focused on microbiome-based medicines, raised $15 million in seed funding on Tuesday. The company will use the money to advance its trial for oncology therapeutics, as well as to continue developing its preventive medicine for infants.
What if we captured the spirit and urgency of Covid-19 research to cure cancer?
Covid-19 stands as a litmus test for pushing the boundaries of standardized research processes. Let’s use this shared focus, urgency, and the new partnerships being forged, to invigorate and accelerate cancer research.
Is the gold rush in immunotherapy trials good?
Developing a unique strategy backed by a strong scientific background, robust preclinical and early phase clinical data, and well-designed clinical trials will go a long way in this crowded race.